Simbec-Orion   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Merthyr Tydfil United Kingdom (1974)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2000
NCT00004219
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Seirian-Simbec | Simbec Orion | Simbec-Orion Clinical Pharmacology | Simbec-Orion Group | Simbec Research | Simbec Research Ltd (Simbec) | SimbecRresearch Ltd.

Active Ingredients

Drugs in Phase 4 Trials (1)

fluoroestradiol (Cerianna) (1 trial)

Drugs in Phase 3 Trials (8)

Key: Simbec-Orion (3) Acquired (5)

gemcitabine (gemzar) (1 trial)

granisetron (kytril) (1 trial)

gv 1001 (1 trial)

lerisetron (1 trial)

methoxyflurane (penthrane) (1 trial)

multivirus (cmv, ebv, adv)-specific t cells (1 trial)

propofol (diprivan) (1 trial)

remimazolam (Byfavo) (1 trial)

Drugs in Phase 2 Trials (6)

Key: Simbec-Orion (3) Acquired (3)

aldesleukin (Proleukin) (1 trial)

cytisine (3 trials)

imatinib (gleevec) (1 trial)

modified vaccinia ankara-5t4 vaccine (1 trial)

trovafloxacin (trovan) (1 trial)

Zelasudil (2 trials)

Drugs in Phase 1 Trials (48)

Key: Simbec-Orion (44) Acquired (4)

acetaminophen (tylenol) (1 trial)

adc-3680 (1 trial)

aluminum hydroxide (Gaviscon) (1 trial)

atx2417 (1 trial)

ax-024 (2 trials)

ax-158 (1 trial)

azasetron (1 trial)

aztreonam (azactam) (1 trial)

bn201 (1 trial)

budesonide (rhinocort) (2 trials)

ceftazidime (fortaz) (1 trial)

clonidine (catapres) (1 trial)

Dexketoprofen (1 trial)

diclofenac (voltaren) (1 trial)

dolasetron (anzemet) (1 trial)

estradiol (progynon depot) (1 trial)

fdl169 (2 trials)

formoterol (foradil) (2 trials)

gbs-nn/nn2 (1 trial)

glycopyrronium (robinul) (2 trials)

gmc-252-l-lysine (2 trials)

hrbmp4 (1 trial)

hydrocortisone (solu-cortef) (3 trials)

hydroxyurea (hydrea) (1 trial)

ibuprofen (motrin) (6 trials)

itraconazole (sporanox) (1 trial)

m01zh09 (1 trial)

metoprolol (lopressor) (1 trial)

naproxen (naprosyn) (1 trial)

nicotine (nicorette) (1 trial)

nitroglycerin (transderm-nitro) (1 trial)

nitrous oxide (1 trial)

oc-000459 (2 trials)

oligog cf-5/20 (1 trial)

olorofim (3 trials)

piperacillin (pipracil) (1 trial)

pnubiovax (1 trial)

pseudoephedrine (Benylin) (1 trial)

rdc5 (1 trial)

spr720 (1 trial)

spr741 (1 trial)

tazobactam (Zosyn) (1 trial)

testosterone (delatestryl) (1 trial)

tiotropium (spiriva) (1 trial)

tromethamine (tham) (1 trial)

ue2343 (1 trial)

urea (5 trials)

zh9pa (1 trial)

Drugs in Other Trials (2)

rabeprazole (pariet) (1 trial)

surufatinib (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Pain (Phase 1)

Adrenal Hyperplasia, Congenital (Phase 1)

Adrenal Insufficiency (Phase 1)

Adrenogenital Syndrome (Phase 1)

Aspergillosis (Phase 1)

Cystic Fibrosis (Phase 1)

Demyelinating Diseases (Phase 1)

Diabetes Mellitus, Type 2 (Phase 1)

Ear Diseases (Phase 1)

Erectile Dysfunction (Phase 1)

Fever (Phase 1)

Fibrosis (Phase 1)

Hepatic Insufficiency (Phase 1)

Hyperplasia (Phase 1)

Hypersensitivity (Phase 1)

Hypogonadism (Phase 1)

Labyrinth Diseases (Phase 1)

Labyrinthitis (Phase 1)

Liver Failure (Phase 1)

Lung Diseases, Obstructive (Phase 1)

Nausea (Phase 3)

Neoplasms, Germ Cell and Embryonal (Phase 3)

Neuritis (Phase 1)

Optic Neuritis (Phase 1)

Pneumococcal Infections (Phase 1)

Pulmonary Disease, Chronic Obstructive (Phase 1)

Renal Insufficiency (Phase 1)

Renal Insufficiency, Chronic (Phase 1)

Seminoma (Phase 3)

Streptococcal Infections (Phase 1)

Typhoid Fever (Phase 1)

Vomiting (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 69
  • # of Trial APIs: 65